RxDoctor Payments Data

Drew Wilkins, PA

Physician Assistant · Round Rock, TXNPI 1598310021

Payments from drug & device makers

$8,710in general payments, 2019–2025

Across 360 payments — averaging $24.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Medtronic$2K
  • Johnson & Johnson$1K
  • Sumitomo Pharma America, Inc.$662
  • Teleflex LLC$575
  • Astellas Pharma US Inc$527
  • plus $3K from 32 others

What the payments were for

  • Travel & lodging$6067%
  • Food & beverage$7,85990%
  • Education$2453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,710 in reported general payments places this provider in the 95th percentile of 8,308 physician assistant providers in Texas.

See all physician assistant providers in Texas

Medicare billing

Part B allowed, 2024
$111,001
Medicare patients
548
Services billed
3,449

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron309$257,034
GemtesaVibegron172$156,429
ElmironPentosan Polysulfate Sodium19$66,736
Mirabegron ErMirabegron50$39,682
Estradiol350$21,196
NitrofurantoinNitrofurantoin Macrocrystal213$7,873
Solifenacin Succinate166$7,305
Fosfomycin Tromethamine39$5,511
Potassium Citrate ErPotassium Citrate41$5,133
Oxybutynin Chloride ErOxybutynin Chloride191$4,879
Finasteride220$3,224
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst135$2,916
Cephalexin162$2,757
Tamsulosin Hcl148$2,441
Alfuzosin Hcl ErAlfuzosin Hcl98$2,119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$527$257,034309 claims
Sumitomo Pharma America, Inc.Gemtesa$662$156,429172 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,308 physician assistant providers in Texas.

Other physician assistant in Round Rock

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →